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Abstract
Background: Treatment of patients with hemophilia has advanced over the past dec-
ades, but it is unknown whether this has resulted in a normal life expectancy in the 
Netherlands.
Objective: This observational cohort study aimed to assess all-cause and cause-
specific mortality in patients with hemophilia in the Netherlands between 2001 and 
2018 and to compare mortality and life expectancy with previous survival assess-
ments from 1973 onward.
Patients/methods: All 1066 patients with hemophilia who participated in a nation-
wide survey in 2001 were followed until July 2018.
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1  | INTRODUC TION
Hemophilia is a hereditary disease caused by a deficiency of clotting 
factor VIII or IX. The introduction of clotting factor concentrates in 
the 1970s1-3 and other improvements such as prophylactic treat-
ment, home treatment, and low dose immune tolerance drastically 
improved life expectancy of patients.2
Unfortunately, exposure to human immunodeficiency virus (HIV) 
and hepatitis C virus (HCV) through contaminated blood products 
in the 1980s led to a sharp increase in mortality.4-10 Through the 
use of viral inactivation techniques, as well as the introduction of 
recombinant factor replacement products, the transmission of both 
HIV and HCV has been halted since 1992.2 From 1999 onward, he-
mophilia treatment in the Netherlands was gradually centralized and 
quality criteria were introduced in comprehensive hemophilia treat-
ment centers.11 In addition, dosages for prophylactic treatment have 
steadily increased since the 1970s.12 It is still insufficiently known 
whether these treatment advances have resulted in a completely 
normal life expectancy in the Netherlands.
This observational cohort study aimed to evaluate all-cause and 
cause-specific mortality in patients with hemophilia in the Netherlands 
from 2001 to 2018 and to compare mortality and life expectancy over 
the past 45 years. In addition, we investigated potential determinants 
of mortality of patients with hemophilia during this period.
2  | METHODS
2.1 | Study design
This was an observational cohort study following patients from 
1973 to 2018. From 1973 to 2001, three cohort studies evaluated 
mortality of patients with hemophilia in the Netherlands.9,10,13 The 
studies were performed from 01 January 1973 to 01 January 1986 
(the 1973–1986 cohort); 02 January 1986 to 31 May 1992 (the 
1986–1992 cohort); and 01 June 1992 to 30 June 2001 (the 1992–
2001 cohort). The current study followed patients who participated 
in a nationwide survey from 01 July 2001 to 01 July 2018. An invita-
tion to participate in the survey was sent to all 1567 known patients 
with hemophilia via their hemophilia physician or the Netherlands 
Hemophilia Patient Society. In total, 1066 patients (68%) com-
pleted the survey.9 The present study was approved in 2018 by the 
Committee of Medical Ethics of Leiden University Medical Center.
2.2 | Patient characteristics at inclusion
All male patients with mild, moderately severe, and severe hemo-
philia A and B who participated in the 2001 survey were included. 
The following self-reported information, obtained from the 2001 
patient survey, was collected at baseline: date of birth, hemophilia 
Results: Information on 1031 individuals (97%) was available, of whom 142 (14%) de-
ceased during follow-up. Compared with the general Dutch male population, mortality 
of patients with hemophilia was still increased (standardized mortality ratio: 1.4, 95% 
confidence interval: 1.2–1.7). Intracranial bleeding and malignancies were the most com-
mon causes of death. Estimated median life expectancy of patients with hemophilia was 
77 years, 6 years lower than the median life expectancy of the general Dutch male popu-
lation (83 years). Over the past 45 years, death rates of patients with hemophilia have 
consistently decreased, approaching the survival experience of the general population. 
Over the past decades, mortality due to human immunodeficiency virus and hepatitis C 
virus infections has decreased, death due to intracranial hemorrhages has increased, and 
death due to ischemic heart disease has remained consistently low over time.
Conclusions: Survival in patients with hemophilia in the Netherlands has improved 
over time but is still lower than that of the general population.
K E Y W O R D S
hemophilia, hepatitis C, HIV, life expectancy, mortality
Essentials
• This study aimed to assess mortality in patients with 
hemophilia.
• Patients with hemophilia who participated in a survey in 
2001 were followed until 2018.
• Despite a decrease in death rates, hemophilia is still as-
sociated with a lower life expectancy.
• Intracranial hemorrhage deaths have increased and is-
chemic heart deaths remain low.
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severity, HIV status, and HCV status. If the self-reported data on HIV 
or HCV were missing, then it was obtained from the medical files.
Hemophilia severity was categorized as severe (<0.01 IU/mL), 
moderate (0.01–0.05 IU/mL), or mild (>0.05–0.40 IU/mL). Information 
on hemophilia severity and type were verified from the medical files. 
Patients born after 1985 or who reported no treatment with clotting 
factor between 1979 and 1985 were considered to be HIV negative. 
Patients born after 1992 or who reported no treatment with clotting 
factor before 1992 were considered to be HCV negative. If HIV/HCV 
status was missing, the information was obtained from the medical 
files. HCV status was categorized as “never infected with HCV,” “HCV 
infection cleared,” and “chronic hepatitis C.” As a double-check, HCV 
status as reported by the patients was compared with HCV status 
from the medical files for a random sample of patients (N = 92).
2.3 | Follow-up and outcomes
Patients were followed from 01 July 2001 until 01 July 2018 or until 
their last known hospital visit. Date of death and cause of death 
were obtained from the medical files. The primary cause of death, 
as written on the death certificate, was not directly available, but 
the same information was also reported in the patients’ medical file 
at the time of death. Causes of death were then manually classi-
fied according to the 10th revision of the International Classification 
of Injuries, Diseases and Causes of Death-10 (ICD-10).14 All-cause 
mortality, cause-specific mortality, and life expectancy of the gen-
eral male population of the Netherlands for the years 1973 to 2017 
were retrieved from the Dutch Central Bureau of Statistics (CBS).15
2.4 | All-cause mortality, cause-specific 
mortality, and life expectancy
The standardized mortality ratio (SMR) is a measure of the change in 
mortality in a given population, with respect to a reference population. 
SMRs were calculated for the years 2001 to 2018 to estimate the risk 
of all-cause and cause-specific death among patients compared to the 
general male population, while adjusting for the age distributions of 
the two populations. The SMR is calculated by dividing the observed 
number of deaths in a study population by the expected number of 
deaths in the study population (which is based on the age distribution 
of the study population and the age-specific death rates of the general 
male population). When calculating cause-specific SMRs, other causes 
of death were censored. To assess all-cause and cause-specific death 
rates over time, we calculated crude death rates for the current and 
previous cohort studies, stratified by 15-year age categories.
The median life expectancy at birth for the 2001–2018 cohort 
was calculated from a lifetime survival curve using age as the time 
scale. To calculate median life expectancy, patients had to survive 
until the start of the study observation period (2001). A standard 
analysis of the data would have induced a type of bias, which is some-
times called length bias.16 To correct for this problem, we adjusted 
for left truncation, ie, patients were included in the analysis from the 
start of the study observation period instead of their date of birth. 
Median life expectancy was defined as the age at which cumulative 
survival was 50%. To assess changes in median life expectancy over 
time, information on median life expectancy for the previous cohort 
studies was obtained from previously published data.9,10,13
2.5 | Potential determinants of mortality
Crude and adjusted associations between hemophilia severity/HIV 
status/HCV status and mortality were assessed with the Cox pro-
portional hazards model, in the standard way, using time on study as 
the time scale and with patients being included in the risk set of the 
model from the time of study entry (2001). Participants with missing 
values were excluded from the analysis.
2.6 | Sensitivity analysis
Severely ill patients may not have participated in the 2001 survey, 
which could have led to an underestimation of death rates during 
follow-up. We examined a possible “healthy cohort effect” by per-




In the current cohort study, we included 1031 out of 1066 (97%) 
patients with available data. Thirty-five patients with missing follow-
up data were excluded. Eighty-seven percent of patients had hemo-
philia A and 13% had hemophilia B (Table 1). In total, 412 patients 
(40%) suffered from severe hemophilia, 175 (17%) from moderate 
hemophilia, and 444 (43%) from mild hemophilia. In 2001, 29 pa-
tients were known to be infected with HIV (3%) and 336 patients 
had chronic hepatitis C (33%).
In the random sample of 92 patients of whom HCV status was 
verified from medical records, 92% (85/92) accurately reported their 
hepatitis C status. Stratified by HCV status, 93%, 75%, and 100% 
correctly reported their HCV status in patients with chronic HCV, 
patients who previously cleared the virus, and patients who were 
never infected, respectively. Median follow-up time was 17.0 years 
(min-max: 0.3–17.4) and the mean age at baseline was 33.9 years 
(standard deviation [SD]: 20.5, min-max: 0.1–89.3) in 2001. For com-
parison, the mean age of the Dutch male population in 2001 was 
37.1 years. The age distribution of the study population and the 
general male population in the Netherlands in 2001 is presented in 
Figure S1 in supporting information. The total number of deaths per 
age group in the study population is presented in Figure S2 in sup-
porting information.
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3.2 | All-cause mortality
In total, 142 patients died during follow-up (14%) at a median age 
of 69.8 years (min-max: 16.4–98.0). A life-time survival curve for 
the study cohort is presented in Figure 1. The overall crude death 
rate was 8.9 deaths per 1000 person-years. The crude death rate in 
the general male population was 8.2 per 1000 person-years in the 
period 2001–2017. Overall, age-standardized mortality in patients 
with hemophilia was 40% higher compared with the general male 
population (SMR 1.4, 95% confidence interval [CI] 1.2–1.7; Table 2).
Crude death rates for the period 1973–2018, stratified by age, 
are presented as a graph (Figure 2) and as a table (Table 3). Overall, 
crude death rates followed a decreasing trend for all age categories. 
For the period 1973–2018, crude death rates changed from 0.7 to 0 
deaths per 1000 person-years for persons aged 0 to 14 years, 2.4 to 
0.8 deaths per 1000 person-years for persons aged 15 to 29 years, 
4.7 to 2.3 deaths per 1000 person-years for persons aged 30 to 
44 years, 13.8 to 19.4 and then to 8.1 deaths per 1000 person-years 
for persons aged 45 to 59 years and 57.9 to 33.7 deaths per 1000 
person-years for persons aged 60 years and older.
3.3 | Cause-specific mortality
From 2001 to 2018, frequent causes of death were non-hepatic 
malignancies (26%) and intracranial bleeding (14%). Acquired immu-
nodeficiency syndrome (AIDS; 2%), chronic liver disease (7%), and 
hepatocellular carcinoma (7%) were less frequent causes of death 
(Table 2). In comparison with the general male population, mortality 
due to AIDS (SMR 27.9, 95% CI 5.8–81.6) and due to HCV infection 
(SMR 13.2, 95% CI 6.3–24.2 for hepatocellular carcinoma, SMR 9.1, 
95% CI 4.3–16.6 for chronic liver disease) were increased (Table 2). In 
addition, mortality due to intracranial bleeding was increased (SMR 
12.8, 95% CI 7.8–19.8). Mortality due to ischemic heart disease was 
F I G U R E  1   Lifetime survival curve for the 2001 to 2018 
cohort. The figure shows the survival curve for patients with mild, 
moderate, and severe hemophilia, using age as the time scale. The 
cumulative probability of survival is shown on the y-axis, the age in 
years is shown on the x-axis
TA B L E  2   All-cause and cause-specific SMR in patients with 
hemophilia from the Netherlands between 2001 and 2018
Cause of death Na (%) SMR (95% CI)b 
All-cause mortality 142 (100) 1.4 (1.2--1.7)
AIDS 3 (2) 27.9 (5.8--81.6)
Hepatocellular carcinoma 10 (7) 13.2 (6.3--24.2)
Chronic liver disease 10 (7) 9.1 (4.3--16.6)
Ischemic heart disease 3 (2) 0.3 (0.1--0.9)
Ischemic stroke 1 (1) 1.1 (0.03--6.0)
Intracranial bleeding 20 (14) 12.8 (7.8--19.8)
Malignancies (non-hepatic) 37 (26) 1.0 (0.7--1.4)
All other causesc  33 (23) Not applicable
Unknown 25 (18) Not applicable
Abbreviations: AIDS, acquired immunodeficiency virus; CI, confidence 
intervals; SMR, standardized mortality ratios.
aNumber of deaths. 
bStandardized mortality ratio, ratio of the observed and expected 
number of deaths and 95% confidence intervals. 
cBacterial infections (11); gastrointestinal bleeding, intra-abdominal 
bleeding, or pericardial bleeding (6); sudden cardiac death (5); trauma (3); 
chronic heart failure (2); suicide/substance abuse (3); or other causes (3). 
TA B L E  1   Patient characteristics at baseline (2001)
Baseline variable N = 1031
Mean age (SD, min-max) 33.9 (20.5, 
0.1--89.3)




Type of hemophilia (n, %)
Hemophilia A 893 (87)
Hemophilia B 138 (13)








HIV infection (n, %)
No (in 2001) 984 (95)
Yes (in 2001) 29 (3)
Unknown 18 (2)
HCV infection (n, %)
Never infected with HCV (in 2001) 581 (56)
HCV infection cleared (in 2001) 96 (9)
Chronic hepatitis C (in 2001) 336 (33)
Unknown 18 (2)
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency 
virus; SD, standard deviation.
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decreased (SMR 0.3, 95% CI 0.1–0.9) while mortality due to ischemic 
stroke was similar (SMR 1.1, 95% CI 0.03–6.0) compared to the general 
male population. Last, mortality due to non-hepatic malignancies was 
also similar to that of the general male population (SMR 1.0, 95% CI 
0.7–1.4).
Cause-specific crude death rates over the past 45 years are pre-
sented in Table 4. Mortality due to AIDS was first reported in the 
period 1986 to 1992, reaching its peak in the period 1992 to 2001, 
and decreased thereafter. A similar pattern is seen for chronic liver 
disease, although the decrease in mortality after 2001 is less pro-
nounced. Mortality due to ischemic heart disease was low in all co-
horts between 1973 and 2018.
3.4 | Median life expectancy
Median life expectancy from 1973 to 2018 is presented in Figure 3 
and additional information on the number of deaths/total person-
time is presented in Table 5. Median life expectancy of the cohort 
increased from 66 years in 1973–1986 to 77 years in 2001–2018, 
a gain of 11 years. In comparison, median life expectancy of the 
general male population increased from 79 years to 83 years dur-
ing the same time frame (a gain of 4 years). For the 2001–2018 co-
hort, median life expectancy of patients with severe hemophilia was 
73 years (SMR 2.4, 95% CI 1.8–3.0), whereas median life expectancy 
F I G U R E  2   Crude death rates over time. The line chart shows 
the crude death rates (per 1000 person-years) for different age 
categories, stratified by study cohort. The accompanying table (Table 
3) shows the total number of deaths, total person-time, and resulting 
death rate for different age categories, stratified by study cohort
TA B L E  4   Cause-specific crude death rates (per 1000 person-years) over time
Cause of death
1973-1986 (N = 717, 
PYa  = 7788)
1986-1992 (N = 919, 
PYa  = 5753)
1992-2001 (N = 967, 
PYa  = 8868)
2001-2018 (N = 1066, 
PYa  = 15 909)
nb  Death ratec  nb  Death ratec  nb  Death ratec  nb  Death ratec 
AIDS 0 0 12 2.09 24 2.71 3 0.19
Hepatocellular carcinoma NR NR NR NR 5 0.56 10 0.63
Chronic liver disease 0 0 5 0.87 10 1.13 10 0.63
Ischemic heart disease 1 0.13 0 0 6 0.68 3 0.19
Ischemic stroke 3 0.39 0 0 0 0 1 0.06
Intracranial bleed 3 0.39 9 1.56 4 0.45 20 1.26
Non-hepatic malignancies 13 1.67 7 1.22 12 1.35 37 2.33
aPY, person-years. 
bn, number of deaths. 
cDeath rate per 1000 person-years, NR, not reported in original publication. 
TA B L E  3   Deaths, person-time, and death rates for different age categories, stratified by study cohort
Age 
category










0--14 1 1530 0.7 0 873 0 0 452 0 0 1920 0
15--29 7 2978 2.4 6 1887 3.2 1 995 1.0 3 3630 0.8
30--44 9 1906 4.7 10 1797 5.6 8 1246 6.4 8 3424 2.3
45--59 11 799 13.8 8 839 9.5 18 929 19.4 33 4075 8.1
60+ 15 259 57.9 21 372 56.5 16 466 34.3 98 2906 33.7
aN, deaths. 
bPY, person-years. 
cCrude death rate per 1000 person-years. 
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was 80 years for patients with moderate hemophilia (SMR 1.1, 95% 
CI; 0.7–1.7) and 79 years for patients with mild hemophilia (SMR 1.0, 
95% CI 0.8–1.4). Although patients with severe hemophilia had the 
lowest median life expectancy, they also showed the biggest gains 
after 2001 (59 years in the 1992–2001 cohort versus 73 years in the 
2001–2018 cohort).
3.5 | Potential determinants of mortality
Compared with patients with mild hemophilia, mortality in patients 
with severe hemophilia was 80% higher (adjusted hazard ratio [HR] 
1.78, 95%CI: 1.08–2.94; Table 6). Twenty-nine patients were HIV 
positive in 2001, 8 patients died during follow-up. Three patients 
died due to AIDS-related complications, two patients died due to 
HCV-related complications, and three patients died due to other 
causes. Compared with HIV-negative patients, mortality among 
HIV-positive patients was increased (adjusted HR 2.65, 95% CI: 
1.26–5.58; Table 6). In total, 336 patients were HCV positive in 
2001. Compared with HCV-negative patients, mortality among 
HCV-positive patients was slightly increased (adjusted HR 1.25, 95% 
CI: 0.85–1.83; Table 6).
3.6 | Sensitivity analysis
The sensitivity analysis excluding the first 3 years of follow-up 
yielded similar results as the overall analysis (Table S1 in supporting 
information).
4  | DISCUSSION
From 1973 to 2019, life expectancy slowly increased, except for the 
period 1986 to 2001 (which coincides with the HIV/HCV epidemic). 
This temporary dip in life expectancy was, as expected, strongest in 
patients with severe hemophilia (who were most exposed to clot-
ting factor products). Overall, the life expectancy of patients with 
hemophilia increased by 11 years versus 4 years for the general male 
population. The differences in mortality rates between time periods 
were most pronounced in the older age groups (Figure 2). This was 
most likely simply due to the high baseline risk of dying in older pa-
tients. However, mortality is still increased compared to the general 
male population.
The cause of the decrease in mortality is most likely a combina-
tion of two main factors: the increased prophylactic dosages and the 
F I G U R E  3   Median life expectancy in patients with hemophilia in the Netherlands between 1973 and 2018. The line chart shows 
the median life expectancy of several groups per study cohort. The life expectancy is shown on the y-axis, while the four study cohorts 
are shown on the x-axis. The upper line represents the median life expectancy of the Dutch general male population over time. The 
accompanying table (Table 5) shows the number of deaths and total person-time of all groups for each study cohort
TA B L E  5   The number of deaths and total person-time for each study cohort, stratified by severity
1973--1986 1986--1992 1992--2001 2001--2018
Deaths PYa  Deaths PYa  Deaths PYa  Deaths PYa 
All patients 43 7776 45 5753 94 8314 142 15 909
Severe hemophilia 20 3649 19 2396 47 3259 65 6406
Moderate hemophilia 10 1861 11 1070 15 1454 22 2683
Mild hemophilia 13 2266 15 2287 32 3600 55 6819
aPY, person-years. 
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decrease in HCV- and HIV-related deaths over time. Evidence from 
the literature shows that integrated care most likely also decreases 
mortality.17 We hypothesized that this would also be the case in 
our study; however, it was impossible to estimate the effect of in-
tegrated care on mortality directly as there were no patients that 
were treated outside of this care model in our study (ie, there was no 
control group to compare against our care model).
Our findings are in line with a study among Italian patients with 
hemophilia, which showed a similar decrease over time (SMR 2.0 95% 
CI 1.5–2.5 from 1990–1999; SMR 1.1 95% CI 0.8–1.4 from 2000–
2007).18 A study among Brazilian patients of the period 2000–2014 
reported a SMR of 1.13 (95% CI: 1.01–1.16), the same outcome as 
that of the 2000–2007 Italian cohort.19 However, it should be noted 
that SMRs from different populations cannot be compared directly 
when the reference populations are not the same.20 Compared to 
the Italian cohort, a similar HCV-related death rate (1.12 deaths per 
1000 person-years) and a higher HIV-related death rate (0.84 deaths 
per 1000 person-years) than in our study was reported.18
In our study, 20 out of 142 patients died due to intracranial bleeding 
(14% of total deaths), a 13-fold increase compared to the general male 
population. The proportion of patients that died due to intracranial 
bleeding was similar for patients with severe hemophilia (2.4%, 95% 
CI 1.2–4.5) and mild hemophilia (2.0%, 95% CI 1.0–3.9). A European/
Australian cohort study that followed 2709 non-severe hemophilia A 
patients who were treated with factor VIII from 1996 to 2010 reported 
a 3.5-fold increased risk (95% CI 2.0–5.8), compared to the general pop-
ulation.21 As only patients with non-severe hemophilia were included, 
the lower mortality risk seems plausible. A recent retrospective study 
from Brazil based on mortality data from the entire male population 
for the period 2001 to 2014 found more similar results, as 137 out of 
784 deaths in this cohort (17.5%, 95% CI 14.9–20.3) were due to intra-
cranial bleeding.19 Intracranial hemorrhages in neonates are a known 
complication of hemophilia,22-24 but these patients were not included 
in our study. In our population, median age at death from intracranial 
bleed was similar to other causes (67 versus 68 years). Further studies 
are needed to mitigate the risk for intracranial bleeding.
Hemophilia potentially complicates treatment of age-related con-
ditions such as malignancies and ischemic heart disease, which are 
becoming more common as the population ages.25-29 For example, 
patients with a malignancy may need additional hemostatic replace-
ment during surgical interventions or after chemotherapy-induced 
thrombocytopenia. Bleeding symptoms will also develop at an earlier 
stage in patients with gastrointestinal malignancies.30 In our cohort, 
the incidence of deaths due to non-hepatic malignancies is now simi-
lar to that of the Dutch male population. This is most likely due to the 
fact that patients are living longer, and due to fewer hemophilia-re-
lated deaths like bleeding-related complications or HCV/HCV.
Based on the literature, it seems that patients with hemophilia 
have an unfavorable cardiovascular risk profile, compared to the 
general population.31,32 In our cohort, the mortality due to ischemic 
heart disease was lower than in the general population, which is also 
in line with literature.30 The low clotting factor levels may hinder 
thrombus formation at the site of plaque rupture.33 The optimal ev-
idence-based anti-platelet/anti-coagulant therapy to reduce throm-
botic risk as well as bleeding risk has not yet been identified.30
Hemophilia severity, HIV status, and HCV status were inde-
pendently associated with mortality. Compared to HCV-negative pa-
tients, the increased risk of mortality for HCV-positive patients was 
relatively minor. This is probably because the vast majority of pa-
tients were successfully treated with either (peg) interferon-based 
treatment and/or the newer direct acting antivirals. Pre-treatment 
severity of fibrosis is strongly associated with mortality after suc-
cessful treatment.34 As information on the extent of liver damage 
was not available, we were not able to assess this in our dataset.
Our study has several strengths. First, due to the availability of 
data from 1972 onward we could study trends in mortality during the 
TA B L E  6   Mortality rates and hazard ratios, according to HIV status and HCV status in 2001--2018
Group N Deaths (%) PYa 
Crude rate (per 1000 
PYa )




Overall 1031 142 (13.8) 15 909 8.9 — —
Mild 444 55 (12.4) 6819 8.1 ref ref
Moderate 175 22 (12.6) 2683 8.2 1.00 (0.61-1.64) 1.24 (0.63-2.44)b 
Severe 412 65 (15.8) 6406 10.2 1.28 (0.89-1.83) 1.78 (1.08-2.94)b 
HIV–e  984 127 (12.9) 15 260 8.3 ref ref
HIV + e  29 8 (27.6) 415 19.3 2.33 (1.14-4.76) 2.65 (1.26-5.58)c 
HCV–f  677 61 (9.0) 10 652 5.7 ref ref
HCV + f  336 74 (22.0) 4997 14.8 2.58 (1.84-3.62) 1.25 (0.85-1.83)d 
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus.
aPerson years. 
bAdjusted for age. 
cAdjusted for age, HCV status, and hemophilia severity. 
dAdjusted for age, HIV status, and hemophilia severity. 
eHIV status was unknown in 18 patients. 
fHCV status was unknown in 18 patients. 
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past 45 years. Second, this study included the majority of patients 
with hemophilia in the Netherlands, with little loss to follow-up (3%) 
during the period 2001 to 2018.
Our study also has limitations. Other important determinants 
of mortality such as inhibitor status, immune tolerance induction, 
bleeding phenotype, joint status, and prophylaxis were not assessed. 
Lastly, as we were not able to collect information on all possible con-
founding factors (such as bleeding phenotype, treatment adherence, 
the level of cirrhosis, inhibitor status, prophylaxis, etc.) some resid-
ual confounding may still exist. In our cohort, we only reported the 
combined results for hemophilia A and B. However, some retrospec-
tive studies have reported that patients with hemophilia B have a 
milder phenotype, but this has not been confirmed in subsequent 
studies.35 Also, there were only 29 patients with HIV, with only 
three deaths due to AIDS. However, the incidence of AIDS in the 
general population was far lower, resulting in a very high SMR of 
27.9 (95% CI: 5.8–81.6). Due to the small sample size, the estimate 
of the SMR is not very precise (hence the wide confidence intervals 
around the estimate). Furthermore, as some information was self-re-
ported, there was a risk of misclassification bias. To reduce this bias, 
hemophilia type, severity, and HCV status were checked from the 
medical files. In the case of HCV status, this was done for a random 
sample of patients (N = 92). Results showed that the self-reported 
HCV status was correct in most cases (92%). In addition, life expec-
tancy estimates should be interpreted with caution as these are al-
ways future projections based on current trends. It is expected that 
age-specific mortality rates will further decrease over time (despite 
the current transient effect of the COVID-19 epidemic on mortality) 
due to improvements in health care and novel treatment options. 
For example, direct-acting antivirals that are used to treat HCV have 
an almost 100% success rate.36 Lastly, compared to treatment with 
clotting factor products, novel non-gene therapy options such as 
emicizumab offer better bleeding management (especially for pa-
tients with an inhibitor) and possibly a better safety profile as well.37
In conclusion, a decrease in mortality and an increase in life ex-
pectancy in patients with hemophilia in the Netherlands over the 
period 1973 to 2018 was seen. However, survival is still lower than 
that of the general population and warrants further improvements 
in hemophilia care.
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